Immunogenicity of Haemophilus influenzae type b conjugate vaccine in allogeneic bone marrow recipients.
A randomized study was conducted in 40 allogeneic marrow recipients to compare the immunogenicity of two Haemophilus influenzae type b (Hib) vaccines (either the Hib capsular polysaccharide [Hib-CPS] or tetanus toxoid-conjugated Hib-CPS [Hib-CPS-T]). A second injection consisted of Hib-CPS-T. Before immunization, 3 patients had serum antibody levels > 1 microgram/mL. After the first injection, the response was better after Hib-CPS-T than after Hib-CPS but lower than in normal subjects; a number of patients lacked any IgG antibody response, especially after Hib-CPS. Of patients who received two injections of Hib-CPS-T, 85% achieved an antibody concentration > or = 1 microgram/mL. Hib-CPS-T induced a response in IgG2-deficient patients whereas Hib-CPS alone did not. IgG antibodies predominantly belonged to the IgG1 subclass. The antibody response was better in patients immunized late after graft. This study shows that Hib-CPS-T is more immunogenic than Hib-CPS in marrow recipients.
Barra
A
A
Laboratory of Immunology and Immunopathology (Centre National de la Recherche Scientifique, Associated Unit 1172), University Hospital, Poitiers, France.
Cordonnier
C
C
Preziosi
M P
MP
Intrator
L
L
Hessel
L
L
Fritzell
B
B
Preud'homme
J L
JL
D000328:Adult; D001428:Bacterial Vaccines / Q000276:immunology / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation / Q000276:immunology*; D005260:Female; D005500:Follow-Up Studies; D006192:Haemophilus Infections / Q000276:immunology* / Q000517:prevention & control; D006193:Haemophilus influenzae / Q000276:immunology*; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood; D008297:Male; D011135:Polysaccharides, Bacterial / Q000276:immunology; D013745:Tetanus Toxoid / Q000276:immunology / Q000627:therapeutic use*; D014184:Transplantation, Homologous; D014614:Vaccines, Synthetic / Q000276:immunology / Q000627:therapeutic use*
D001428:Bacterial Vaccines; D007074:Immunoglobulin G; D011135:Polysaccharides, Bacterial; D013745:Tetanus Toxoid; D014614:Vaccines, Synthetic